Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

4.79
+0.24005.27%
Post-market: 4.790.00000.00%18:22 EDT
Volume:2.22M
Turnover:10.54M
Market Cap:368.90M
PE:-3.58
High:4.89
Open:4.43
Low:4.37
Close:4.55
Loading ...

Altimmune Inc - Phase 2 AUD Trial for Pemvidutide Expected in Q2 2025

THOMSON REUTERS
·
14 Mar

ALT Resources PLC Publishes Annual Report for 2024

TIPRANKS
·
11 Mar

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

PR Newswire
·
09 Mar

Altimmune (ALT) Initiated with a Hold at William Blair

TIPRANKS
·
06 Mar

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Mar

William Blair Initiates Altimmune at Market Perform

MT Newswires Live
·
28 Feb

Altimmune Initiated at Market Perform by William Blair

Dow Jones
·
28 Feb

Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.
·
28 Feb

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

PR Newswire
·
28 Feb

BRIEF-Altimmune Files For Mixed Shelf Offering Of Up To $400 Million- SEC Filing

Reuters
·
28 Feb

Altimmune files $400M mixed securities shelf

TIPRANKS
·
28 Feb

Altimmune Inc Files for Mixed Shelf Offering of up to $400 Mln- SEC Filing

THOMSON REUTERS
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Warby Parker (WRBY)

TIPRANKS
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: NovoCure (NVCR), Altimmune (ALT)

TIPRANKS
·
28 Feb

Altimmune Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Altimmune Q4 2024 GAAP EPS $(0.33), Inline, Sales $5.00K Down From $37.00K YoY, Cash, Cash Equivalents And Short-term Investments Of $131.9M

Benzinga
·
27 Feb

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Business Wire
·
27 Feb

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

GlobeNewswire
·
26 Feb

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

THOMSON REUTERS
·
25 Feb